Efficacy of Zerbutinib,Lenalidomide combined with R-CHOP Chemotherapy in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
Objective To explopre the efficacy of Zebutinib and Lenalidomide combined with R-CHOP chemotherapy in the treatment of relapsed and refractory B-cell non Hodgkin lymphoma.Methods Ninety-eight patients with relapsed refractory B-cell NHL treated in Zhangjiagang Hospital of Traditional Chinese Medicine from January 2018 to January 2023 were selected as the study objects,and were randomly divided into observation group and control group,with 49 cases in each group.All patients were treated with R-CHOP regimen chemotherapy.The control group received additional treatment with lenalidomide on top of the R-CHOP regimen,while the observation group received additional treatment with Zebutinib combined with lenalidomide on top of the R-CHOP regimen.Compareing the clinical efficacy of two groups of patients and conducting a one-year follow-up to compare their overall survival rate and progression free survival rate.The immune function,PLR,NLR before and after treatment and incidence of adverse reactions between the two groups of patients were comparde.Results The objective remission rate of observation group was 87.76%higher than that of control group 71.43%(P＜0.05),and the 1-year progression-free survival rate was 81.63%higher than that of control group 59.18%(P＜0.05).CD4+/CD8+,immunoglobulin G(IgG)and immunoglobulin A(IgA)were increased in 2 groups after treatment(P＜0.05),but there was no statistical significance between observation group and control group(P＞0.05).After treatment,the levels of NLR and PLR in the two groups were decreased,and the observation group was lower than the control group,the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of fever,thrombocytopenia,gastrointestinal function injury,leukopenia,neutropenia and alopecia between the two groups(P＞0.05).Conclusion The combination of Zebutinib,Lenalidomide,and R-CHOP chemotherapy has better clinical efficacy in the treatment of relapsed and refractory B-cell non Hodgkin lymphoma,can improve the progression free survival rate of patients,has no significant adverse effects on immune function,and can improve the tumor inflammation status of patients,with higher safety.
ZebutinibLenalidomideR-CHOP schemeRecurrent refractory B-cell non Hodgkin lymphoma
国家科技期刊平台
NSTL
万方数据
